CDP COPT Defense posts narrow Q4 2025 EPS miss shares rise modestly as investor sentiment holds steady Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement TNDM Tandem posts far narrower than expected Q4 2025 loss yet shares slip 115 percent today